KORU Medical Systems Inc

Análisis de la acción KORU Medical Systems Inc (KRMD)

$3.030

-0.222 (-7.34%)Al cierre

Loading chart…
Máximo
3.310
Apertura
3.310
Precio medio ponderado por volumen
3.09
Volumen
143.77K
Capitalización
130.43M
Mínimo
2.920
Importe
443.78K
EV/EBITDA, TTM
36.88

KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers.

Análisis de IA of KORU Medical Systems Inc (KRMD)

Comprar

KORU Medical Systems Inc is a good buy right now due to its current price of $3.05, which is significantly below its 52-week high of $6.61, indicating potential for recovery. The company has shown a gross margin of 63.39% in Q2 2026, reflecting strong profitability. Additionally, analysts project a price target of $6, suggesting a potential upside of 96.7% from the current price. However, the main risk is the forward P/E ratio of 74.63, indicating high expectations for future earnings that may not materialize.

Métricas de valoración

El PER previsto actual de KORU Medical Systems Inc (KRMD) es 76.34, frente a su media de 5 años de -7.42.

PER previsto

Valor razonable
Media 5A P/E
-7.42
P/E actual
76.34
Sobrevalorada
108.26
Infravalorada
-123.09

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
-24.07
EV/EBITDA actual
36.88
Sobrevalorada
59.60
Infravalorada
-107.75

Precio/ventas previsto

Infravalorado
Media 5A P/S
4.07
P/S actual
2.53
Sobrevalorada
5.09
Infravalorada
3.05

Escenarios de precio de Alphio AI para KRMD

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%KRMD

$3.23

Precio del escenario

B

Base

Base · 50%KRMD

$2.98

Precio del escenario

B

Bajista

Bajista · 25%KRMD

$2.84

Precio del escenario

Ballenas con KRMD en cartera

F

First Light Asset Management, LLC

+ Con en carteraKRMD

+0.00%

Rentabilidad a 3 meses

Cronología de eventos

2026-08-05 (ET)

17:30:00

Company Reiterates Positive EBITDA Outlook for FY26

17:30:00

Koru Reports Q2 Revenue of $12.0M, Exceeding Expectations

2026-05-06 (ET)

16:20:00

Koru Medical Affirms FY26 Revenue View of $47.5M-$50M

16:20:00

Koru Medical Reports Q1 Revenue of $11.77M

2026-03-12 (ET)

16:40:00

KORU Medical Reports Q4 Revenue of $10.9M

Noticias

Preguntas frecuentes sobre KRMD, respondidas por Alphio AI

KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

KORU Medical Systems Inc is a good buy right now due to its current price of $3.05, which is significantly below its 52-week high of $6.61, indicating potential for recovery. The company has shown a gross margin of 63.39% in Q2 2026, reflecting strong profitability. Additionally, analysts project a price target of $6, suggesting a potential upside of 96.7% from the current price. However, the main risk is the forward P/E ratio of 74.63, indicating high expectations for future earnings that may not materialize.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar